Amyloid Focus In FDA Alzheimer’s Guidance Gets Mixed Response

By Jessica Karins / June 10, 2024 at 5:59 PM
Major drug companies involved in developing drugs for Alzheimer’s disease reacted positively to FDA’s recently updated draft guidance on development of treatments for the disease, but the agency drew criticism from investors in a less prominent Alzheimer’s drug developer for its focus on amyloid beta plague reduction as a surrogate for slowing the progress of the disease. Anti-amyloid drugs are currently dominating the landscape of Alzheimer’s treatment development, despite some controversy among scientists and resistance from CMS to covering the...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.